Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OPKO HealthLTS:0KCS -1.81%50 Revenue per Share is $0.77 as of Jun. 2026. GuruFocus rates LTS:0KCS with a GF Score™ of 50/100 and a GF Value™ of $1.12 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, OPKO Health ranks worse than 73.68% on this metric.
OPKO Health's revenue per share for the
three
months ended in Jun. 2026 was $0.22.
OPKO Health's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.77.
Warning Sign:
OPKO Health Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of OPKO Health was -11.30% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -16.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -21.00% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -4.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for OPKO Health's Revenue per Share or its related term are showing as below:
LTS:0KCS'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -74.5 Med: 23.2 Max: 152
Current: -16.7
During the past 13 years, OPKO Health's highest 3-Year average Revenue Per Share Growth Rate was 152.00% per year. The lowest was -74.50% per year. And the median was 23.20% per year.
LTS:0KCS's 3-Year Revenue Growth Rate is ranked worse than 73.68% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.7
vs LTS:0KCS: -16.70
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
OPKO Health Revenue per Share Related Terms
OPKO Health Revenue per Share Historical Data
* Premium members only.
The historical data trend for OPKO Health's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KCS vs CSTL, FRNM, FLGT: Revenue per Share Comparison
For the Diagnostics & Research subindustry, OPKO Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OPKO Health PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where OPKO Health's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
OPKO Health's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPKO Health (LTS:0KCS) has a Revenue per Share of $0.77 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on OPKO Health and its competitors. According to the industry distribution chart, OPKO Health ranks #140 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 73.7%.
Is OPKO Health's Revenue per Share too high?
OPKO Health's current Revenue per Share is $0.77. The Medical Diagnostics & Research industry median Revenue per Share is 1.70. OPKO Health's value of $0.77 is 54.7% below this industry median. Based on the distribution chart, OPKO Health ranks #140 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, OPKO Health has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Revenue per Share compare to CSTL and FRNM?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #140 out of 190 companies for Revenue per Share. This places OPKO Health in the lower half of its industry. The industry median Revenue per Share is 1.70. OPKO Health's value of $0.77 is 54.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.70, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OPKO Health's current Revenue per Share of $0.77 is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on OPKO Health and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OPKO Health's current Revenue per Share is $0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.12, compared to a current price of $1.63 — trading 45.5% above its estimated fair value. The current Revenue per Share is $0.77 and 54.7% below the Medical Diagnostics & Research industry median of 1.70. OPKO Health's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current Revenue per Share is $0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OPKO Health (LTS:0KCS) Overvalued in 2026?
Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued.
The current stock price of $1.63 is trading 45.5% above its estimated GF Value™ of $1.12.
GuruFocus considers OPKO Health to be Significantly Overvalued.
Key valuation signals for LTS:0KCS:
Revenue per Share: $0.77
GF Value™: $1.12 vs. price of $1.63 (45.5% above fair value)
Industry Position: 54.7% below the Medical Diagnostics & Research median (#140 of 190)
No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
50GF Score
Get the complete analysis for LTS:0KCS
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KCS has been successfully added to your 
